Glenmark Pharmaceuticals announced its Q1 results for the April–June quarter of financial year 2026, reporting a steep 86% fall in net profit to ₹47 crore compared to the same period last year.
Despite the sharp drop in profitability, the company’s revenue saw a marginal increase, reflecting steady sales performance amid challenging market conditions.
The announcement comes during an active earnings season, with nearly 665 companies set to release their April–June quarter results. Alongside Glenmark, other notable names reporting include Vodafone Idea (Vi), Indian Oil Corporation (IOC), Ashok Leyland, AstraZeneca Pharma, Coffee Day Enterprises, Easy Trip Planners, GKB Ophthalmics, Inox Wind, Patanjali Foods, and Sanstar.
Also Read: Proposed H-1B Rule Change Could Alter Indian IT Hiring Landscape
While revenue growth remained slightly positive, the sharp fall in net profit indicates possible cost pressures or lower margins for the company. Investors will be closely watching Glenmark’s upcoming quarters for signs of recovery in profitability.
Click here to explore: Glenmark Pharma
IndiGo Shares Bounce Back as DGCA Offers Partial Relief on Pilot Duty Rules Amid Nationwide…
Shares of Yes Bank and Union Bank of India gained up to 3% on December…
DGCA Steps In With Temporary Rule Relaxation as IndiGo Flight Cancellations Deepen Across India In…
Petronet LNG’s stock saw a sharp upmove on December 4, rising more than 4 percent…
The domestic equity market staged a sharp recovery on Friday as the Sensex surged over…
India’s financial markets have entered a phase defined by conflicting forces, as the Reserve Bank…
This website uses cookies.